Precision BioSciences (NASDAQ:DTIL) CFO John Alexander Kelly Sells 8,149 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CFO John Alexander Kelly sold 8,149 shares of the stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total transaction of $31,292.16. Following the sale, the chief financial officer owned 125,883 shares of the company’s stock, valued at approximately $483,390.72. This represents a 6.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

John Alexander Kelly also recently made the following trade(s):

• On Wednesday, January 21st, John Alexander Kelly sold 15,213 shares of Precision BioSciences stock. The stock was sold at an average price of $4.03, for a total transaction of $61,308.39.

Precision BioSciences Stock Down 3.7%

Precision BioSciences stock traded down $0.15 during trading hours on Friday, hitting $3.78. 38,118 shares of the stock traded hands, compared to its average volume of 219,939. Precision BioSciences, Inc. has a one year low of $3.53 and a one year high of $8.82. The firm’s 50-day moving average price is $4.14 and its two-hundred day moving average price is $5.01. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 1.35. The company has a market cap of $86.45 million, a PE ratio of -0.45 and a beta of 1.31.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $60.00.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in DTIL. HBK Sorce Advisory LLC bought a new position in Precision BioSciences during the 4th quarter worth about $38,000. Engineers Gate Manager LP bought a new position in shares of Precision BioSciences during the fourth quarter valued at approximately $43,000. Occudo Quantitative Strategies LP purchased a new position in Precision BioSciences during the fourth quarter valued at approximately $52,000. Vanguard Personalized Indexing Management LLC purchased a new position in Precision BioSciences during the third quarter valued at approximately $72,000. Finally, Miller Financial Services LLC raised its stake in Precision BioSciences by 50.0% in the fourth quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after buying an additional 5,000 shares in the last quarter. Institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.